iiinova — where your digital self keeps evolving

Ajay Major, MD, MBA @majorajay.bsky.social · 2h

Pembro-GVD R/R cHL five-year f/u @bloodjournal.bsky.social - 39 pts; 41% 1° refractory - ORR 100% (CR 95%) - 95% proceeded to ASCT - 5-yr PFS 91%, OS 94% (!!!) Long-term remissions/cures with CPI + ASCT in R/R cHL. Interesting question remains re: 2nd-line regimens with use of frontline CPI. #lymsm

100

Ajay Major, MD, MBA @majorajay.bsky.social · 2h

Real-world N-AVD older cHL #lymsm - 327 pts: 81 (25%) 60+ yr, med age 70 - EOT ORR 88% (CR 83%) - 1-yr PFS 92%, OS 99% - OS inferior if age 60+ (not surprising) - GCSF 82%, FN 12% (52% G3+ neutropenia), infx 27% - irAEs 29%, nivo d/c'd 17%, 10% all tx d/c'd for AEs

110

Ajay Major, MD, MBA @majorajay.bsky.social · 11/09/2026

Huge thanks as well to the @cctsi.bsky.social Clinical Faculty Scholars Program and the @ash.hematology.org Clinical Research Training Institute for their grantsmanship training as well.

011

Ajay Major, MD, MBA @majorajay.bsky.social · 11/09/2026

Elated to share that our NCI K08 has been selected for funding! Deeply grateful to @hawkeyestudts.bsky.social and my colleagues @cuhematology.bsky.social @accordsresearch.bsky.social for their persistence and coaching in bringing this lymphoma PRO-focused training award to fruition. #lymsm

140

Reposted by Ajay Major, MD, MBA

CU Anschutz Cancer Center @cucancercenter.bsky.social · 03/09/2026

In a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF

Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.

073

Reposted by Ajay Major, MD, MBA

Mark Harden @markharden.bsky.social · 02/09/2026

CAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth

news.cuanschutz.edu

CAR T-Cell Therapy is a Blood Cancer Breakthrough. But What About Quality of Life?

A CU Anschutz Cancer Center member and a resident physician study how patients feel two years after CAR T-cell therapy.

022

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

We also found: - responders had better long-term social role function - pts >65: slower early physical recovery, but long-term HRQoL improved regardless of age - women started w/ worse HRQoL but had greater improvements in fatigue & global physical health by 2 yrs

100

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

Provocatively, we found that patients who later responded to CAR-T by D+90 had worse fatigue at D+15 vs nonresponders. By D+30, fatigue was similar. Hypothesis-generating & suggests acute post-CAR-T patient-reported fatigue may be a novel “PRO-marker” of response. #lymsm #mmsm

100

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

We primarily found that HRQoL improved over time after CAR-T, with long-term improvements in: - physical function - social role functioning - sleep disturbance Important for counseling: survivors can have meaningful QoL recovery over time. #tcellrx #lymsm #mmsm

100

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

Study design: - prospective CAR-T biobank with embedded PROMIS Global Health-10 + PROMIS-29 instruments - 83 pts - 49% aggressive lymphoma, 43% MM, 4% B-ALL - median age 66 - 95% had ≥2 prior LOT - surveys from baseline thru D+720 #lymsm #mmsm

100

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...

162

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

Thiotepa-ASCT associated w/ better survival in 6-mo landmark MV analysis: - 2-yr PFS 70% for CNS isolated, 29% for synch, 30% for de novo SCNSL. - propensity matched: thiotepa-ASCT better than CAR-T: PFS HR 0.46 - CAR-T 2-yr PFS: overall 19%, CNS isolated 41%, synch 15% 3/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

Supports treating isolated CNS relapse like PCNSL. #lymsm In de novo SCNSL: - no clear PFS/OS difference between common induction regimens - IT chemo with MR-CHOP in leptomeningeal disease did not clearly improve CNS response/PFS/OS, though small N 2/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

Multicenter international SCNSL outcomes 🧵 @cwynkate2.bsky.social: - 1139 pts, 35 centers: 537 de novo SCNSL, 395 isolated CNS relapse, 207 synch CNS/systemic dx - 2-yr PFS: 40% de novo, 44% CNS isolated, 16% synch (!!) - CNS isolated w/ very low risk of systemic dx (6%) #lymsm 1/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

- worse outcomes: ECOG 2+, ⬆️LDH, refractory dz, trial ineligible, PD <6 mos post-CAR - CRS 33% (G≥3 5%), ICANS 13% (G≥3 rare), ICU admit 17% Much worse outcomes & toxicities in RW setting. #lymsm ashpublications.org/bloodadvance... 2/2

ashpublications.org

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab

Key PointsPatients who would have been ineligible for the clinical trial demonstrated inferior PFS and OS.Compared with pivotal trials, this real-world ana

000

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

RW epcoritamab R/R aNHL outcomes (CUBIC Consoritum) @bloodadvances.bsky.social: - 157 pts, 9 centers, med age 70, 55% prior CAR - 46% EPCORE NHL-1 ineligible - ORR 50% (CR 32%) - mPFS 3.5 mos, mOS 7.6 mos; 1-yr PFS/OS 29%/38% 1/2

100

Ajay Major, MD, MBA @majorajay.bsky.social · 10/08/2026

Mosun/pola in R/R MCL post BTKi @BloodPortfolio - 42 pts, 67% high Ki67, 48% TP53mut, 26% prior CAR - ORR 88% (CR 79%), post-CAR ORR 91%, TP53mut ORR 100% - mPFS 18.6 mos, mOS 20.7 mos - CRS 43% (all G1-2), ICANS 7% (all G1-2) - 5 (12%) G5 infection-related AEs (3 COVID, 1 WNV, 1 PNA) #oncsky 1/2

111

Ajay Major, MD, MBA @majorajay.bsky.social · 08/08/2026

Congratulations to my mentee Dr. Elisa Hofmeister @cuinternalmed.bsky.social on publication of this comprehensive review of patient-reported outcomes from novel lymphoma immunotherapies. Harmonized PRO and tolerability measurement frameworks are needed. #lymsm pubmed.ncbi.nlm.nih.gov/42565955/

121

Ajay Major, MD, MBA @majorajay.bsky.social · 04/08/2026

Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org. CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."

232

Ajay Major, MD, MBA @majorajay.bsky.social · 03/08/2026

Full paper here: www.sciencedirect.com/science/arti...

000

Ajay Major, MD, MBA @majorajay.bsky.social · 03/08/2026

Fixed-duration ven after cBTKi progression in CLL @bloodjournals.hematology.org - 79 pts, 71% VR, 82% 2/3L, 20% TP53mut - ORR 78% (CR 41%) - 18-mo PFS 79%, TTNT 80%, OS 84% - VR subgroup: 18-mo PFS 78%, OS 87% - VO subgroup too small Good RW data to support tx sequencing. #oncsky #medsky

141

Reposted by Ajay Major, MD, MBA

ACCORDS @accordsresearch.bsky.social · 14/07/2026

Congratulations to Ajay Major, MD, MBA, who is the lead author on a new publication from The Oncologist! Read Now: tinyurl.com/3src42t6 #ACCORDSIntegration #HealthServicesResearch #CancerResearch

$New Publication | "Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma" was published in The Oncologist by Ajay Major, MD, MBA, Assistant Professor, Department of Medicine, Division of Hematology.$

041

Ajay Major, MD, MBA @majorajay.bsky.social · 05/07/2026

TME may explain pola-R-CHP benefit in DLBCL #lymsm - post-hoc RNAseq analysis across 3 RCTs: >1200 pts - low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP - in M1-low pts, pola-R-CHP improved PFS v R-CHOP: HR 0.59 1/2

112

Ajay Major, MD, MBA @majorajay.bsky.social · 23/06/2026

Huge thank you to @cucancercenter.bsky.social for featuring our latest publication on patient-reported time toxicity from bispecific antibodies in FL & DLBCL, including how dosing schedules can meaningful impact time burden for patients & care partners. #lymsm news.cuanschutz.edu/cancer-cente...

news.cuanschutz.edu

Time Toxicity: Weighing the Benefits of Cancer Therapies Against Time Demands on Patients

A new study led by CU Anschutz Cancer Center member Ajay Major, MD, MBA, surveyed patients with relapsed lymphoma about the time burdens of treatments.

100

Ajay Major, MD, MBA @majorajay.bsky.social · 23/06/2026

Speaking today at the IVI PCORI-funded Convening on time toxicity in patients with cancer. Excited to highlight our latest publication on measuring time toxicity as a patient-reported outcome: academic.oup.com/oncolo/artic... #lymsm #oncsky

010

Ajay Major, MD, MBA @majorajay.bsky.social · 22/06/2026

VO remains good option that balances efficacy & toxicities. AVO with uIGHV from AMPLIFY may present better option in that subset. #lymsm ashpublications.org/blood/articl... 2/

ashpublications.org

000

Ajay Major, MD, MBA @majorajay.bsky.social · 22/06/2026

5-year CLL13/GAIA follow-up: - 5-yr PFS: GIV 81%, GV 70%, RV 57%, CIT 51% - no OS differences - figure has uIGHV (B) vs mIGHV (C) - cardiac AEs highest with GIV - GV/RV had faster QoL improvements vs CIT; GIV QoL gains occurred later (more tx-related side effects) 1/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 16/06/2026

- FACT-Lym improved early by C4 & was durable thru f/u Supports survival outcomes + QoL improvements w/ R-pola-glo in historically challenging cohort. #EHA2026 library.ehaweb.org/eha/2026/eha... 2/

library.ehaweb.org

LONGITUDINAL PATIENT-REPORTED OUTCOMES HIGHLIGHT IMPROVED QUALITY... by Rebecca Wurm-Kuczera

EHA Library; Wurm-Kuczera R. Jun 11 2026; 4209055;

000